Literature DB >> 12163229

Graves' ophthalmopathy: a rational approach to treatment.

Wilmar M Wiersinga1, Mark F Prummel.   

Abstract

The past decade has witnessed great progress in our understanding of Graves' opthalmopathy (GO), although its precise immunopathogenesis remains an enigma. Several clinical studies have provided a more rational basis for treatment of this distressing disease, which significantly lowers the quality of life. A management plan tailored to the patient's needs can be devised according to the severity and activity of the eye disease. In active GO, immunosuppression might be considered. The combination of intravenous pulses of methylprednisolone and retrobulbar irradiation improves eye changes in 88% of patients, and is well tolerated. Once the disease has become inactive, rehabilitative surgery could be performed (orbital decompression, strabismus surgery and eyelid surgery, in that order). The patient should be reassured that functional and cosmetic improvement of eye changes is feasible, but restoration can require one to two years. To a certain extent, refraining from smoking prevents the development or worsening of GO.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12163229     DOI: 10.1016/s1043-2760(02)00622-7

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  14 in total

1.  Immunotherapy for Graves' orbitopathy: easy enthusiasm, but let's keep trying.

Authors:  L Bartalena; M L Tanda
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

2.  Development of criteria for evaluating clinical response in thyroid eye disease using a modified Delphi technique.

Authors:  Raymond S Douglas; Angelo Tsirbas; Mark Gordon; Diana Lee; Nicole Khadavi; Helene Chokron Garneau; Robert A Goldberg; Kenneth Cahill; Peter J Dolman; Victor Elner; Steve Feldon; Mark Lucarelli; Jimmy Uddin; Michael Kazim; Terry J Smith; Dinesh Khanna
Journal:  Arch Ophthalmol       Date:  2009-09

Review 3.  The evaluation and treatment of graves ophthalmopathy.

Authors:  Marius N Stan; James A Garrity; Rebecca S Bahn
Journal:  Med Clin North Am       Date:  2012-02-22       Impact factor: 5.456

Review 4.  Graves' orbitopathy: imperfect treatments for a rare disease.

Authors:  Luigi Bartalena
Journal:  Eur Thyroid J       Date:  2013-11-20

Review 5.  Radiotherapy for Graves' disease. The possible role of low-dose radiotherapy.

Authors:  Meritxell Arenas; Sebastià Sabater; Pedro Lara Jiménez; Àngels Rovirosa; Albert Biete; Victoria Linares; Montse Belles; Julià Panés
Journal:  Rep Pract Oncol Radiother       Date:  2016-03-04

6.  Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?

Authors:  P Grassi; D Strianese; R Piscopo; R Pacelli; G Bonavolontà
Journal:  Ir J Med Sci       Date:  2017-01-03       Impact factor: 1.568

7.  Human TSH receptor ligands as pharmacological probes with potential clinical application.

Authors:  Susanne Neumann; Bruce M Raaka; Marvin C Gershengorn
Journal:  Expert Rev Endocrinol Metab       Date:  2009-11-01

8.  Radiotherapy in the treatment of Graves ophthalmopathy-to do it or not?

Authors:  Aneta Zygulska
Journal:  J Ocul Biol Dis Infor       Date:  2009-10-06

9.  Compressive Optic Neuropathy and Repeat Orbital Decompression: A Case Series.

Authors:  Courtney Y Kauh; Shivani Gupta; Raymond S Douglas; Victor M Elner; Christine C Nelson; Leslie M Niziol; Alon Kahana
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Sep-Oct       Impact factor: 1.746

10.  Total thyroidectomy as a method of choice in the treatment of Graves' disease - analysis of 1432 patients.

Authors:  Toplica Bojic; Ivan Paunovic; Aleksandar Diklic; Vladan Zivaljevic; Goran Zoric; Nevena Kalezic; Vera Sabljak; Nikola Slijepcevic; Katarina Tausanovic; Nebojsa Djordjevic; Dragana Budjevac; Lidija Djordjevic; Aleksandar Karanikolic
Journal:  BMC Surg       Date:  2015-04-09       Impact factor: 2.102

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.